GSK lifts forecasts on strong launch of RSV vaccine
GSK has today raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine.
Business
• 01 Nov 23
